SlideShare a Scribd company logo
1 of 60
Download to read offline
Ten-Color, 14 Antibody Flow cytometry
(FCM) Screening Tube for
Lymphoproliferative Disorders and
Myelodysplasia (MDS) – Related Changes in
Bone Marrow Samples
EMAIL: Amr.Rajab@uhn.ca
Amr Rajab, BSc, MLT, QCYM (ASCP)
Clinical Flow Cytometry Laboratory
Laboratory Medicine Program
Toronto General Hospital/University Health Network
Ontario, Canada
TOPICS
• Development
• Validation for LL/AL screening (Phase 1)
 Optimization of sample preparation
 Titration of antibodies
 Verification of cocktail stability
 Instrument setup and compensation
 Comparison study
 Analysis
 Cases
• Validation for MDS Screening (Phase 2)
• Current & Future Developments
GOAL
 Develop a 10 Color, 14 antibody Flow
cytometry (FCM) screening tube that
correctly identifies lymphoproliferative
disorders and myelodysplasia (MDS) –
related changes in bone marrow samples
FLOW CYTOMETRY LAB - UHN
Section A Section B
Tests performed AL & LL CD34, CD4/CD8 & PNH
Number of samples- 2014
Referred in samples
8143
40%
7174
40%
Instruments Two 3L 10C Navios Two 1L 5C FC500
Number of Technologists 7 1
Total number of samples processed during 2014= 15317
Why the new screening tube (ST)? (1)
1. To be used for immunophenotyping of
hypocellular samples, dry taps, FNAs, and
body fluids (e.g. CSF).
2. To be used for “referred in” samples (mainly
bone marrow aspirates and peripheral blood
samples) not accompanied by sufficient clinical
information, provisional diagnosis, or prepared
smears (50% of referred samples)
Why the new ST? (2)
Why the new ST? (3)
• These samples were usually screened using the
UHN lymphoma protocol (2 tubes, 20 antibodies).
• The outcome determined how much further
investigation was needed.
• 50% do not show any pathological population.
Tube FITC PE ECD PC5.5 PC7 APC APC-
AF700
APC-
AF750
PB KO
B-cell kappa lambda CD19 CD38 CD20 CD34 CD23 CD10 CD5 CD45
T-cell CD57 CD11c CD8 CD3 CD2 CD56 CD7 CD4 CD5 CD45
Similar approach has been applied by other groups in 4-
color, 6-color, 8-color and 10-color settings –
Focusing on lymphoid population
• Quijano S, …etc. Spanish Group for the Study of CNS Disease in NHL.Identification
of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved
sensitivity of flow cytometry. J Clin Oncol. 2009 Mar 20;27(9):1462-9.
• Preijers FW…etc. B. OMIP-010: a new 10-color monoclonal antibody panel for
polychromatic immunophenotyping of small hematopoietic cell samples. Cytometry A.
2012 Jun;81(6):453-5.
• Costa ES, …etc. A new automated flow cytometry data analysis approach for the
diagnostic screening of neoplastic B-cell disorders in peripheral blood samples with
absolute lymphocytosis. Leukemia. 2006 Jul;20(7):1221-30
• van Dongen JJ,…etc. EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708).
EuroFlow antibody panels for standardized n-dimensional flow cytometric
immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012
Sep;26(9):1908-75.
• Hedley BD, Keeney M, Popma J, Chin-Yee I. Novel lymphocyte screening tube
using dried monoclonal antibody reagents. Cytometry B Clin Cytom. 2015 May 4
SCREENING TUBE
10 COLORS, 14 ANTIBODIES
• Enumerate Major Populations:
• Blasts
• B- lymphocytes, T- lymphocytes,
• NK cells
• Monocytes
• Neutrophils
• Enumerate Sub-populations:
• T-Helper cells, T- Suppressor cells
• CD34+/CD19+ B- cell progenitors
• CD34+/CD33+ myeloid progenitors
• CD33+/CD10+ mature granulocytes
• B-cell clonality status: Kappa Lambda
• B-cell maturation status CD20/CD10
expression.
VALIDATION FOR
LYMPHOMA/LEUKEMIA (PHASE 1)
• Optimization of sample preparation
• Titration of antibodies
• Verification of cocktail stability
• Instrument setup and compensation
• Comparison study
VALIDATION FOR LYMPHOMA/LEUKEMIA (PHASE 1)
(Selection of lysing solution)
VALIDATION FOR
LYMPHOMA/LEUKEMIA (PHASE 1)
1. Sample preparation
• Wash cells x 2 with warm PBS
• Resuspend cells in 1% BSA in PBS
• Adjust cells to 5 x109 /L
• Add Ab cocktail to 100ul (5 x105 cells) of sample
• Incubate for 15 minutes in dark at RT.
• Lyse with 1mL VersaLyse (BC ref. IM3648) plus
25 uL IOTest 3 Fixative (BC ref. IM3515)
• Wash and suspend in 1 mL PBS and 12.5 uL
IOTest 3 Fixative (BC ref. IM3515)
VALIDATION FOR
LYMPHOMA/LEUKEMIA (PHASE 1)
(Titration of antibodies)
All antibodies titrated to determine the optimal concentrations
Ab PN Titer (uL)
FITC
CD4 IM0448U 10
Kappa A64828 10
PE
CD8 IM0452U 10
Lambda A64827 10
ECD
CD3 IM2705U 5
CD14 IM2707U 3
PC5.5 CD33 A70198 3
PC7
CD20 IM3629U 5
CD56 A51078 10
APC CD34 IM2472U 5
A700 CD19 A78837 3
A750 CD10 A89310 5
PB CD5 A82790 5
KO CD45 A96416 5
 Optimal signal-to-noise separation
 Minimize background fluorescence
VALIDATION FOR LYMPHOMA/LEUKEMIA (PHASE 1)
(Verification of cocktail stability)
 Antibodies cross reactivity
 Stability over two weeks
VALIDATION FOR LYMPHOMA/LEUKEMIA (PHASE 1)
(Instrument setup)
• FSC/SSC settings were optimized using a whole blood
sample lysed with VersaLyse
• FL1-FL9 were optimized using blood samples stained
with CD4
• FL10 was optimized using blood samples stained with
CD45 KO
VALIDATION FOR LYMPHOMA/LEUKEMIA
(PHASE 1)
(Optimizing Instrument Compensation)
• The compensation matrix was calculated using Kaluza software (BC) and list-
mode files (LMD) from blood samples stained with single CD45 antibodies for
each fluorescence channel .
• Compensation for the screening tube was adjusted using normal BMA stained
with the full screening panel.
• FlowCheck Pro (Beckman Coulter)
• FlowSet Pro (Beckman Coulter)
• Compensation verifier
VALIDATION FOR LYMPHOMA/LEUKEMIA
(PHASE 1)
(Instrument QC)
VALIDATION FOR LYMPHOMA/LEUKEMIA
(PHASE 1)
(Comparison study)
Study Overview
The validation was done using 32 patient samples
The samples included 17 BMA, 11 blood samples (PB), 3 lymph node
cell suspensions (LNB) and one body fluid (BF, pleural fluid).
16 female and 16 male patients, age 25-93(mean age 57)
Diagnosis included 7 normal/reactive samples (3 BMA, 1 BF and 3
PB), 12 samples with B or T lymphoproliferative disorders (LPD), 1
Multiple myeloma (MM), 6 acute leukemias (AML/ALL), 5 MDS and one
paroxysmal nocturnal hemoglobinuria (PNH).
KALUZA ANALYSIS TEMPLATE
NORMAL BM SAMPLE
Living Cells = NOT Debris
NORMAL BM SAMPLE
(BLAST ANALYSIS)
Dim CD45+CD45-ve
NORMAL BM SAMPLE
(CD45-/dim ANALYSIS)
NORMAL BM SAMPLE
(B-CELL ANALYSIS)
NK = Lymphs AND (NOT CD19+)
NORMAL BM SAMPLE
(T-CELL/ NK ANALYSIS)
NORMAL BM SAMPLE
(Grans & Monos Aanalysis)
KALUZA SELECTED STATISTICS
EXPORT KALUZA STATISTICS
SCREENING TUBE REPORT
FLOW CYTOMETRY LAB - UHN
Paperless reporting
All staff members have access to analysis
software and share drive
Shared drive storage/reporting
Lymphoproliferative neoplasm
B- CLL
FCL
T-LPD
Plasma Cell Neoplasms
ST
MM
Paucicellular Cytologic Specimens (1)
CSF
WBC= 5 x106/L
1,315 events collected
Reactive lymphoid T-cell population
Rajab A, Boerner S, da Cunha Santos G, Geddie W, Ko HM, Porwit A. Ten-Color 14
antibody flow cytometry panel for immunophenotyping of paucicellular cytologic
specimens. Cytometry Part B: Clinical Cytometry, 2013, Oct 25, 84, (6): 419
(abstract).
CSF
WBC= 2 x106/L
3,262 events collected
B-cell LPD
Paucicellular Cytologic Specimens (2)
CSF
WBC= 22 x106/L
6,560 events collected
ATLL
Paucicellular Cytologic Specimens (3)
Acute Leukemia
AML
B-ALL
T-ALL
PNH -POSITIVE
CD14
NEGATIVE
PNH-
MONOCYTE
CLONE
VALIDATION FOR LYMPHOMA/LEUKEMIA
(PHASE 1- RESULTS)
(The comparison study showed 100% concordance)
VALIDATION FOR LYMPHOMA/LEUKEMIA (PHASE 1)
SUMMARY (1)
• During August 2012 – December 2013 we have analyzed 1025
samples using ST. In 94% of the cases we could render a final FCM
report and 6% of cases required further immunophenotyping.
• The Screening Tube is capable of enumerating major blood and
bone marrow cell populations.
• It can detect aberrant antigen expression on B-cells (CD5, CD10,
CD20, Kappa/Lambda)
• Establish B-cell clonality status
• Establish B-cell maturation status (CD10/CD20)
• Detecting aberrant expression on T-cells (CD3, CD5, CD4, CD8, &
CD10)
VALIDATION FOR
LYMPHOMA/LEUKEMIA (PHASE 1)
SUMMARY (2)
• The Screening Tube can detect abnormal
Myeloid populations
• The Screening Tube can reduce TAT
• The Screening Tube reduces the need for Hem-
Path consultation
• The Screening Tube can reduce costs by up to
30%
• Unable to detect minor clonal plasma cell
population
Flow cytometry has recently been recommended as a
significant parameter in the integrated diagnostics of
patients with cytopenia and suspected MDS
• Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, del CC, et al. Diagnosis and
treatment of primary myelodysplastic syndromes in adults: recommendations from the European
LeukemiaNet. Blood 2013 Oct 24;122(17):2943-64.
• Porwit A. Role of flow cytometry in diagnostics of myelodysplastic syndromes--beyond the WHO
2008 classification. Semin Diagn Pathol 2011 Nov;28(4):273-82.
• Porwit A, van de Loosdrecht AA, Bettelheim P, Brodersen LE, Burbury K, Cremers E, et al.
Revisiting guidelines for integration of flow cytometry results in the WHO classification of
myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working
Group for Flow Cytometry in MDS. Leukemia 2014 Jun 12.
• Porwit A. Is There a Role for Flow Cytometry in the Evaluation of Patients
With Myelodysplastic Syndromes? Curr Hematol Malig Rep. 2015 Sep;10(3):309-17
VALIDATION FOR MDS SCREENING
(PHASE 2 background)
VALIDATION FOR MDS SCREENING
(PHASE 2 background)
Study enrolled patients from 6 institutions (Europe, USA,
Japan)
417 low grade MDS (with <5% blasts)
380 pathological controls with non-clonal cytopenias
FCM analysis was performed with various antibody
combinations and various flow cytometers
Haematologica 2012; 97(8)
VALIDATION (PHASE 2 background)
FCM score > 2 was significantly associated with MDS diagnosis
High values were associated with multilineage dysplasia,
transfusion dependency and high-risk cytogenetics
Della Porta et al. 2012
FCM- score for MDS using our screening tube
(NORMAL BM)
Gated Myeloblasts in all nucleated cells: 1.6% (If ≥2%, FCM score= 1)
Gated B-cell progenitor in CD34+ cells: 5.3% (If ≤5%, FCM score=1)
Lymphocyte to myeloblast CD45 MFI ratio= 6.4 (If ≤4 or ≥7.5, FCM score=1)
Granulocyte to lymphocyte SSC mode ratio: 8 (If ≤6, FCM score=1)
Total FCM score= 0
FCM- score for MDS (MDS case)
Gated Myeloblasts in all nucleated cells: 3.3 (If ≥2, FCM score= 1)
Gated B-cell progenitor in CD34+ cells: 0.4 (If ≤5, FCM score=1)
Lymphocyte to myeloblast CD45 MFI ratio: 12.5 (If ≤4 or ≥7.5, FCM score=1)
Granulocyte to lymphocyte SSC mode ratio: 4.7 (If ≤6, FCM score=1)
Total FCM score= 4
VALIDATION (PHASE 2)
• 741 BM samples were analyzed within 2013
• Results of MDS score were correlated with morphological and
cytogenetic evaluation in a selected group of 440 bone marrow samples
from patients with full clinical information:
 8 normal BM samples
 207 BM samples hospital controls*
 18 B-cell or plasma cell neoplasm
 33 post treatment for other malignancy
 21 post BM transplant
 47 MPN
 106 samples from patients with MDS or MDS/MPN diagnosis
(based on morphological, cytogenetic and clinical findings)
* Patients with cytopenia(s) with no evidence of underlying malignancy, BM samples with reactive
inflammatory changes or lymphoma staging specimens without lymphoma involvement.
RESULTS- VALIDATION (PHASE 2)
Rajab A, Porwit A. Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features
with one 10-color 14-antibody screening tube. Cytometry B Clin Cytom. 2015 Jul-Aug;88(4):253-60
PPN= 96%
NPV= 82%
PPN= 75%
NPV= 86%
RESULTS- VALIDATION (PHASE 2)
Rajab A, Porwit A. Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features
with one 10-color 14-antibody screening tube. Cytometry B Clin Cytom. 2015 Jul-Aug;88(4):253-60
10 color acute leukemia panel
at University Health Network, Toronto
AML 1 AML 2 AML 3 B-ALL T-ALL cytopl
FITC CD65 CD36 CD71 CD58 CD7 nTdt
PE CD13 CD64 CD11c CD22 CD1a cMPO
ECD CD14 CD56 CD4 CD38 CD8 CD14
PC5.5 CD33 CD33 CD33 CD33 CD3 CD33
PC7 CD34 CD34 CD34 CD34 CD34 CD34
APC CD117 CD123
CD2 CD123 CD2 cCD79a
APC_AlexaF700 CD7 CD19
CD10 CD10 CD10 cCD22
APC_AlexaF750 CD11b CD38
CD235a CD19 CD4 CD19
Pacific_BLUE CD16 HLA-DR CD15 CD20 CD5 cCD3
Krome Orange CD45 CD45 CD45 CD45 CD45 CD45
SCREENING TUBES
CONCLUSION
• Developed 14 MAb 10-color FCM tube can be applied
for a quick screening for aberrant lymphoid populations
and myelodysplasia-related features.
• MDS score 3 or 4 is highly indicative of MDS/MDS-MPN
but can also be seen in MPN.
• Score 2 in patients with differential diagnosis of MDS or
MDS/MPN should prompt further investigation for
myelodysplastic syndrome using comprehensive FCM
panel.
• MDS diagnosis should always be based on integrated
diagnostics (morphology, FCM, cytogenetics)
CURRENT & FUTURE DEVELOPMENTS
A. Improve the accuracy of MDS score
B. Develop Ten-Color 15 Antibody Flow
Cytometry Panel for Immunophenotyping of
Lymphocyte population
Improve the accuracy of MDS score
Porwit A, et al. Revisiting guidelines for
integration of flow cytometry results in the WHO
classification of myelodysplastic syndromes-
proposal from the International/European
LeukemiaNet Working Group for Flow Cytometry
in MDS. Leukemia 2014 Jun 12.
Ten-Color 15 Antibody Flow Cytometry Panel
for Immunophenotyping of Lymphocyte
population
• 80% of LPD cases we diagnosed in 2014 in blood are
CLL/MBL.
Ten-Color 15 Antibody Flow Cytometry Panel for
Immunophenotyping of Lymphocyte population
Ab
FITC CD4 + Kappa
PE CD8 + Lambda
ECD CD3 + CD14
PC5.5 CD5
PC7 CD20 + CD56
APC CD10
APC-A700 CD19
APC-A750 CD200
PB CD57 +CD23
KO CD45
ICCS 2015, Abstract #88, Poster Session 2 on Monday, October 12, 2015
Ten-Color 15 Antibody Flow Cytometry Panel for Immunophenotyping of Lymphocyte population
Amr Rajab, Graeme Quest, Jennifer Leung, Anna Porwit
Department of Laboratory Hematology, University Health Network Toronto, ON, Canada
CLL
MCL
T-cell LGL
AITL
ACKNOWLEDGEMENTS
• Anna Porwit
• Jennifer Leung
• Jessie Leung
• Jordan Ngo
• Josello Mandawi
• Liz Valenzuela
• May Ly
• Sajid Dawji
• Reza Jafari
Thank you for your attention

More Related Content

What's hot

Benign White blood cell (WBC) Disorders
Benign White blood cell (WBC) DisordersBenign White blood cell (WBC) Disorders
Benign White blood cell (WBC) DisordersDr. Varughese George
 
Multiple Myeloma Modified , Dr Gamal Abdul Hamid
Multiple   Myeloma Modified ,  Dr  Gamal  Abdul  HamidMultiple   Myeloma Modified ,  Dr  Gamal  Abdul  Hamid
Multiple Myeloma Modified , Dr Gamal Abdul HamidGamal Abdul Hamid
 
Myeloprolmiferative Neoplasms (2021)
Myeloprolmiferative Neoplasms (2021)Myeloprolmiferative Neoplasms (2021)
Myeloprolmiferative Neoplasms (2021)Ahmed Makboul
 
Bleeding disorders Pathology Dr. UMME HABIBA
Bleeding disorders Pathology Dr. UMME HABIBABleeding disorders Pathology Dr. UMME HABIBA
Bleeding disorders Pathology Dr. UMME HABIBAHabibah Chaudhary
 
Approach to patients with bleeding disorders
Approach to patients with bleeding disordersApproach to patients with bleeding disorders
Approach to patients with bleeding disordersAYM NAZIM
 
Aplastic anaemia checked
Aplastic anaemia checkedAplastic anaemia checked
Aplastic anaemia checkedBALRAM KRISHAN
 
Hypoplastic bone marrow syndromes
Hypoplastic bone marrow syndromesHypoplastic bone marrow syndromes
Hypoplastic bone marrow syndromesAhmed Elshebiny
 
acute myeloid luekemia: Dr Arun Haldia
acute myeloid luekemia: Dr Arun Haldiaacute myeloid luekemia: Dr Arun Haldia
acute myeloid luekemia: Dr Arun HaldiaDr Arun Haldia
 
Myelodysplastic syndrome by dr narmada
Myelodysplastic syndrome by dr narmadaMyelodysplastic syndrome by dr narmada
Myelodysplastic syndrome by dr narmadaNarmada Tiwari
 
486 qualitative disorders of wbc
486 qualitative disorders of wbc486 qualitative disorders of wbc
486 qualitative disorders of wbcNabin Chaudhary
 
platelet function, disorders and its assesment
platelet function, disorders and its assesmentplatelet function, disorders and its assesment
platelet function, disorders and its assesmentFigo Khan
 
Myelodysplastic syndrome
Myelodysplastic syndromeMyelodysplastic syndrome
Myelodysplastic syndromeajayyadav753
 
Platelet disorders summarized. ppt
Platelet disorders summarized. pptPlatelet disorders summarized. ppt
Platelet disorders summarized. pptEMMANUELOKURUT1
 

What's hot (20)

Benign White blood cell (WBC) Disorders
Benign White blood cell (WBC) DisordersBenign White blood cell (WBC) Disorders
Benign White blood cell (WBC) Disorders
 
Multiple Myeloma Modified , Dr Gamal Abdul Hamid
Multiple   Myeloma Modified ,  Dr  Gamal  Abdul  HamidMultiple   Myeloma Modified ,  Dr  Gamal  Abdul  Hamid
Multiple Myeloma Modified , Dr Gamal Abdul Hamid
 
Plasma cell disorders ppt
Plasma cell disorders pptPlasma cell disorders ppt
Plasma cell disorders ppt
 
Myeloprolmiferative Neoplasms (2021)
Myeloprolmiferative Neoplasms (2021)Myeloprolmiferative Neoplasms (2021)
Myeloprolmiferative Neoplasms (2021)
 
Approach to anemia
Approach to anemiaApproach to anemia
Approach to anemia
 
Bleeding disorders Pathology Dr. UMME HABIBA
Bleeding disorders Pathology Dr. UMME HABIBABleeding disorders Pathology Dr. UMME HABIBA
Bleeding disorders Pathology Dr. UMME HABIBA
 
Approach to patients with bleeding disorders
Approach to patients with bleeding disordersApproach to patients with bleeding disorders
Approach to patients with bleeding disorders
 
Acute leukemia; imtiaz
Acute leukemia; imtiazAcute leukemia; imtiaz
Acute leukemia; imtiaz
 
Aplastic anaemia checked
Aplastic anaemia checkedAplastic anaemia checked
Aplastic anaemia checked
 
Sideroblastic anaemia
Sideroblastic anaemiaSideroblastic anaemia
Sideroblastic anaemia
 
Hypoplastic bone marrow syndromes
Hypoplastic bone marrow syndromesHypoplastic bone marrow syndromes
Hypoplastic bone marrow syndromes
 
acute myeloid luekemia: Dr Arun Haldia
acute myeloid luekemia: Dr Arun Haldiaacute myeloid luekemia: Dr Arun Haldia
acute myeloid luekemia: Dr Arun Haldia
 
Aplastic anemia
Aplastic anemiaAplastic anemia
Aplastic anemia
 
Myelodysplastic syndrome by dr narmada
Myelodysplastic syndrome by dr narmadaMyelodysplastic syndrome by dr narmada
Myelodysplastic syndrome by dr narmada
 
Haemolytic anaemia
Haemolytic anaemiaHaemolytic anaemia
Haemolytic anaemia
 
Haematology Myloma.
Haematology Myloma.Haematology Myloma.
Haematology Myloma.
 
486 qualitative disorders of wbc
486 qualitative disorders of wbc486 qualitative disorders of wbc
486 qualitative disorders of wbc
 
platelet function, disorders and its assesment
platelet function, disorders and its assesmentplatelet function, disorders and its assesment
platelet function, disorders and its assesment
 
Myelodysplastic syndrome
Myelodysplastic syndromeMyelodysplastic syndrome
Myelodysplastic syndrome
 
Platelet disorders summarized. ppt
Platelet disorders summarized. pptPlatelet disorders summarized. ppt
Platelet disorders summarized. ppt
 

Viewers also liked

SCREENING TUBEs_ICCS_2016-AR
SCREENING TUBEs_ICCS_2016-ARSCREENING TUBEs_ICCS_2016-AR
SCREENING TUBEs_ICCS_2016-ARAmr Rajab
 
Presentation1 prakt gigi
Presentation1 prakt gigiPresentation1 prakt gigi
Presentation1 prakt gigidamai_uca
 
సమస్యా పూరణలు
సమస్యా పూరణలుసమస్యా పూరణలు
సమస్యా పూరణలుSailaja Akundi
 
Madame Tussauds Portfolio - P&P Projects
Madame Tussauds Portfolio - P&P ProjectsMadame Tussauds Portfolio - P&P Projects
Madame Tussauds Portfolio - P&P ProjectsWilliam Watts
 
Web...planes y demás
Web...planes y demásWeb...planes y demás
Web...planes y demásfrajalumos
 
Native Americans
Native AmericansNative Americans
Native AmericansTee018
 
AlumniPolimi Convention, Roberto Crapelli
AlumniPolimi Convention, Roberto CrapelliAlumniPolimi Convention, Roberto Crapelli
AlumniPolimi Convention, Roberto Crapellialumnipolimi
 
Майстер-клас сирний суп із брокколі - Селіванова
Майстер-клас сирний суп із брокколі - СелівановаМайстер-клас сирний суп із брокколі - Селіванова
Майстер-клас сирний суп із брокколі - СелівановаCatherine Petrova
 
LNG Industry Magazine (Commercial Quality Control The Missing Link)
LNG Industry Magazine (Commercial Quality Control The Missing Link)LNG Industry Magazine (Commercial Quality Control The Missing Link)
LNG Industry Magazine (Commercial Quality Control The Missing Link)Dyplast Products
 

Viewers also liked (14)

SCREENING TUBEs_ICCS_2016-AR
SCREENING TUBEs_ICCS_2016-ARSCREENING TUBEs_ICCS_2016-AR
SCREENING TUBEs_ICCS_2016-AR
 
Presentation1 prakt gigi
Presentation1 prakt gigiPresentation1 prakt gigi
Presentation1 prakt gigi
 
సమస్యా పూరణలు
సమస్యా పూరణలుసమస్యా పూరణలు
సమస్యా పూరణలు
 
Madame Tussauds Portfolio - P&P Projects
Madame Tussauds Portfolio - P&P ProjectsMadame Tussauds Portfolio - P&P Projects
Madame Tussauds Portfolio - P&P Projects
 
Web...planes y demás
Web...planes y demásWeb...planes y demás
Web...planes y demás
 
Native Americans
Native AmericansNative Americans
Native Americans
 
Webs
WebsWebs
Webs
 
AlumniPolimi Convention, Roberto Crapelli
AlumniPolimi Convention, Roberto CrapelliAlumniPolimi Convention, Roberto Crapelli
AlumniPolimi Convention, Roberto Crapelli
 
Master klas golovchenko
Master klas golovchenkoMaster klas golovchenko
Master klas golovchenko
 
Іваненко С.В.
Іваненко С.В.Іваненко С.В.
Іваненко С.В.
 
Майстер-клас сирний суп із брокколі - Селіванова
Майстер-клас сирний суп із брокколі - СелівановаМайстер-клас сирний суп із брокколі - Селіванова
Майстер-клас сирний суп із брокколі - Селіванова
 
Gef - CRYSTAL
Gef - CRYSTALGef - CRYSTAL
Gef - CRYSTAL
 
LNG Industry Magazine (Commercial Quality Control The Missing Link)
LNG Industry Magazine (Commercial Quality Control The Missing Link)LNG Industry Magazine (Commercial Quality Control The Missing Link)
LNG Industry Magazine (Commercial Quality Control The Missing Link)
 
Chapter One
Chapter OneChapter One
Chapter One
 

Similar to SCREENING TUBES

Use of flow cytometric immunophenotyping by teresa lotodo
Use of flow cytometric immunophenotyping by teresa lotodoUse of flow cytometric immunophenotyping by teresa lotodo
Use of flow cytometric immunophenotyping by teresa lotodoKesho Conference
 
Minimal Residual Disease in leukaemia andhematological malignancies
Minimal Residual Disease in leukaemia andhematological malignanciesMinimal Residual Disease in leukaemia andhematological malignancies
Minimal Residual Disease in leukaemia andhematological malignanciessadiya97
 
Flowcytometry
FlowcytometryFlowcytometry
FlowcytometryBadheeb
 
Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Oleg Kshivets
 
Thrombosis Case Study
Thrombosis Case StudyThrombosis Case Study
Thrombosis Case Studyflasco_org
 
Integrated haematopathology
Integrated haematopathology Integrated haematopathology
Integrated haematopathology Dr. Rajesh Bendre
 
Automated cell counter & its quality control
Automated cell counter & its quality controlAutomated cell counter & its quality control
Automated cell counter & its quality controlSaikat Mandal
 
Predict the therapeutic effect of HDAC inhibitor panobinostat on leukemia by ...
Predict the therapeutic effect of HDAC inhibitor panobinostat on leukemia by ...Predict the therapeutic effect of HDAC inhibitor panobinostat on leukemia by ...
Predict the therapeutic effect of HDAC inhibitor panobinostat on leukemia by ...eilosei
 
ROLE OF FLOW CYTOMETRY IN LEUKEMIAS
ROLE OF FLOW CYTOMETRY IN LEUKEMIASROLE OF FLOW CYTOMETRY IN LEUKEMIAS
ROLE OF FLOW CYTOMETRY IN LEUKEMIASHajra Mehdi
 
inmunofenotipo para leucemias linfociticas en perros.pdf
inmunofenotipo para leucemias linfociticas en perros.pdfinmunofenotipo para leucemias linfociticas en perros.pdf
inmunofenotipo para leucemias linfociticas en perros.pdfleroleroero1
 
Clinical diagnosis of chronic myeloid leukemia by real time polymerase chain ...
Clinical diagnosis of chronic myeloid leukemia by real time polymerase chain ...Clinical diagnosis of chronic myeloid leukemia by real time polymerase chain ...
Clinical diagnosis of chronic myeloid leukemia by real time polymerase chain ...Teboho Mooko
 
CDISC journey in Leukemia studies using IWCLL 2008
CDISC journey in Leukemia studies using IWCLL 2008CDISC journey in Leukemia studies using IWCLL 2008
CDISC journey in Leukemia studies using IWCLL 2008Kevin Lee
 
Prof.dr.moh'd sorour bch
Prof.dr.moh'd sorour bchProf.dr.moh'd sorour bch
Prof.dr.moh'd sorour bchmohammed4450
 
Qualitative Flow Cytometric Analysis of Malaysian
Qualitative Flow Cytometric Analysis of MalaysianQualitative Flow Cytometric Analysis of Malaysian
Qualitative Flow Cytometric Analysis of MalaysianMohadese Hashem Boroojerdi
 

Similar to SCREENING TUBES (20)

Use of flow cytometric immunophenotyping by teresa lotodo
Use of flow cytometric immunophenotyping by teresa lotodoUse of flow cytometric immunophenotyping by teresa lotodo
Use of flow cytometric immunophenotyping by teresa lotodo
 
Minimal Residual Disease in leukaemia andhematological malignancies
Minimal Residual Disease in leukaemia andhematological malignanciesMinimal Residual Disease in leukaemia andhematological malignancies
Minimal Residual Disease in leukaemia andhematological malignancies
 
Bjh12067
Bjh12067Bjh12067
Bjh12067
 
Lung Cancer Conference Luxembourg 2013
Lung Cancer Conference Luxembourg 2013Lung Cancer Conference Luxembourg 2013
Lung Cancer Conference Luxembourg 2013
 
CLL - TSH Midyear 2009
CLL - TSH Midyear 2009CLL - TSH Midyear 2009
CLL - TSH Midyear 2009
 
Dr g vassiliou
Dr g vassiliouDr g vassiliou
Dr g vassiliou
 
Nancytomique Wuhan Juin 2013
Nancytomique Wuhan Juin 2013Nancytomique Wuhan Juin 2013
Nancytomique Wuhan Juin 2013
 
Flowcytometry
FlowcytometryFlowcytometry
Flowcytometry
 
Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis
 
Thrombosis Case Study
Thrombosis Case StudyThrombosis Case Study
Thrombosis Case Study
 
Integrated haematopathology
Integrated haematopathology Integrated haematopathology
Integrated haematopathology
 
Automated cell counter & its quality control
Automated cell counter & its quality controlAutomated cell counter & its quality control
Automated cell counter & its quality control
 
World CTC Berlin 2013
World CTC Berlin 2013World CTC Berlin 2013
World CTC Berlin 2013
 
Predict the therapeutic effect of HDAC inhibitor panobinostat on leukemia by ...
Predict the therapeutic effect of HDAC inhibitor panobinostat on leukemia by ...Predict the therapeutic effect of HDAC inhibitor panobinostat on leukemia by ...
Predict the therapeutic effect of HDAC inhibitor panobinostat on leukemia by ...
 
ROLE OF FLOW CYTOMETRY IN LEUKEMIAS
ROLE OF FLOW CYTOMETRY IN LEUKEMIASROLE OF FLOW CYTOMETRY IN LEUKEMIAS
ROLE OF FLOW CYTOMETRY IN LEUKEMIAS
 
inmunofenotipo para leucemias linfociticas en perros.pdf
inmunofenotipo para leucemias linfociticas en perros.pdfinmunofenotipo para leucemias linfociticas en perros.pdf
inmunofenotipo para leucemias linfociticas en perros.pdf
 
Clinical diagnosis of chronic myeloid leukemia by real time polymerase chain ...
Clinical diagnosis of chronic myeloid leukemia by real time polymerase chain ...Clinical diagnosis of chronic myeloid leukemia by real time polymerase chain ...
Clinical diagnosis of chronic myeloid leukemia by real time polymerase chain ...
 
CDISC journey in Leukemia studies using IWCLL 2008
CDISC journey in Leukemia studies using IWCLL 2008CDISC journey in Leukemia studies using IWCLL 2008
CDISC journey in Leukemia studies using IWCLL 2008
 
Prof.dr.moh'd sorour bch
Prof.dr.moh'd sorour bchProf.dr.moh'd sorour bch
Prof.dr.moh'd sorour bch
 
Qualitative Flow Cytometric Analysis of Malaysian
Qualitative Flow Cytometric Analysis of MalaysianQualitative Flow Cytometric Analysis of Malaysian
Qualitative Flow Cytometric Analysis of Malaysian
 

Recently uploaded

Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 

Recently uploaded (20)

Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 

SCREENING TUBES

  • 1. Ten-Color, 14 Antibody Flow cytometry (FCM) Screening Tube for Lymphoproliferative Disorders and Myelodysplasia (MDS) – Related Changes in Bone Marrow Samples EMAIL: Amr.Rajab@uhn.ca Amr Rajab, BSc, MLT, QCYM (ASCP) Clinical Flow Cytometry Laboratory Laboratory Medicine Program Toronto General Hospital/University Health Network Ontario, Canada
  • 2. TOPICS • Development • Validation for LL/AL screening (Phase 1)  Optimization of sample preparation  Titration of antibodies  Verification of cocktail stability  Instrument setup and compensation  Comparison study  Analysis  Cases • Validation for MDS Screening (Phase 2) • Current & Future Developments
  • 3. GOAL  Develop a 10 Color, 14 antibody Flow cytometry (FCM) screening tube that correctly identifies lymphoproliferative disorders and myelodysplasia (MDS) – related changes in bone marrow samples
  • 4. FLOW CYTOMETRY LAB - UHN Section A Section B Tests performed AL & LL CD34, CD4/CD8 & PNH Number of samples- 2014 Referred in samples 8143 40% 7174 40% Instruments Two 3L 10C Navios Two 1L 5C FC500 Number of Technologists 7 1 Total number of samples processed during 2014= 15317
  • 5. Why the new screening tube (ST)? (1) 1. To be used for immunophenotyping of hypocellular samples, dry taps, FNAs, and body fluids (e.g. CSF). 2. To be used for “referred in” samples (mainly bone marrow aspirates and peripheral blood samples) not accompanied by sufficient clinical information, provisional diagnosis, or prepared smears (50% of referred samples)
  • 6. Why the new ST? (2)
  • 7. Why the new ST? (3) • These samples were usually screened using the UHN lymphoma protocol (2 tubes, 20 antibodies). • The outcome determined how much further investigation was needed. • 50% do not show any pathological population. Tube FITC PE ECD PC5.5 PC7 APC APC- AF700 APC- AF750 PB KO B-cell kappa lambda CD19 CD38 CD20 CD34 CD23 CD10 CD5 CD45 T-cell CD57 CD11c CD8 CD3 CD2 CD56 CD7 CD4 CD5 CD45
  • 8. Similar approach has been applied by other groups in 4- color, 6-color, 8-color and 10-color settings – Focusing on lymphoid population • Quijano S, …etc. Spanish Group for the Study of CNS Disease in NHL.Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol. 2009 Mar 20;27(9):1462-9. • Preijers FW…etc. B. OMIP-010: a new 10-color monoclonal antibody panel for polychromatic immunophenotyping of small hematopoietic cell samples. Cytometry A. 2012 Jun;81(6):453-5. • Costa ES, …etc. A new automated flow cytometry data analysis approach for the diagnostic screening of neoplastic B-cell disorders in peripheral blood samples with absolute lymphocytosis. Leukemia. 2006 Jul;20(7):1221-30 • van Dongen JJ,…etc. EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012 Sep;26(9):1908-75. • Hedley BD, Keeney M, Popma J, Chin-Yee I. Novel lymphocyte screening tube using dried monoclonal antibody reagents. Cytometry B Clin Cytom. 2015 May 4
  • 9. SCREENING TUBE 10 COLORS, 14 ANTIBODIES • Enumerate Major Populations: • Blasts • B- lymphocytes, T- lymphocytes, • NK cells • Monocytes • Neutrophils • Enumerate Sub-populations: • T-Helper cells, T- Suppressor cells • CD34+/CD19+ B- cell progenitors • CD34+/CD33+ myeloid progenitors • CD33+/CD10+ mature granulocytes • B-cell clonality status: Kappa Lambda • B-cell maturation status CD20/CD10 expression.
  • 10. VALIDATION FOR LYMPHOMA/LEUKEMIA (PHASE 1) • Optimization of sample preparation • Titration of antibodies • Verification of cocktail stability • Instrument setup and compensation • Comparison study
  • 11. VALIDATION FOR LYMPHOMA/LEUKEMIA (PHASE 1) (Selection of lysing solution)
  • 12. VALIDATION FOR LYMPHOMA/LEUKEMIA (PHASE 1) 1. Sample preparation • Wash cells x 2 with warm PBS • Resuspend cells in 1% BSA in PBS • Adjust cells to 5 x109 /L • Add Ab cocktail to 100ul (5 x105 cells) of sample • Incubate for 15 minutes in dark at RT. • Lyse with 1mL VersaLyse (BC ref. IM3648) plus 25 uL IOTest 3 Fixative (BC ref. IM3515) • Wash and suspend in 1 mL PBS and 12.5 uL IOTest 3 Fixative (BC ref. IM3515)
  • 13. VALIDATION FOR LYMPHOMA/LEUKEMIA (PHASE 1) (Titration of antibodies) All antibodies titrated to determine the optimal concentrations Ab PN Titer (uL) FITC CD4 IM0448U 10 Kappa A64828 10 PE CD8 IM0452U 10 Lambda A64827 10 ECD CD3 IM2705U 5 CD14 IM2707U 3 PC5.5 CD33 A70198 3 PC7 CD20 IM3629U 5 CD56 A51078 10 APC CD34 IM2472U 5 A700 CD19 A78837 3 A750 CD10 A89310 5 PB CD5 A82790 5 KO CD45 A96416 5  Optimal signal-to-noise separation  Minimize background fluorescence
  • 14. VALIDATION FOR LYMPHOMA/LEUKEMIA (PHASE 1) (Verification of cocktail stability)  Antibodies cross reactivity  Stability over two weeks
  • 15. VALIDATION FOR LYMPHOMA/LEUKEMIA (PHASE 1) (Instrument setup) • FSC/SSC settings were optimized using a whole blood sample lysed with VersaLyse • FL1-FL9 were optimized using blood samples stained with CD4 • FL10 was optimized using blood samples stained with CD45 KO
  • 16. VALIDATION FOR LYMPHOMA/LEUKEMIA (PHASE 1) (Optimizing Instrument Compensation) • The compensation matrix was calculated using Kaluza software (BC) and list- mode files (LMD) from blood samples stained with single CD45 antibodies for each fluorescence channel . • Compensation for the screening tube was adjusted using normal BMA stained with the full screening panel.
  • 17. • FlowCheck Pro (Beckman Coulter) • FlowSet Pro (Beckman Coulter) • Compensation verifier VALIDATION FOR LYMPHOMA/LEUKEMIA (PHASE 1) (Instrument QC)
  • 18. VALIDATION FOR LYMPHOMA/LEUKEMIA (PHASE 1) (Comparison study) Study Overview The validation was done using 32 patient samples The samples included 17 BMA, 11 blood samples (PB), 3 lymph node cell suspensions (LNB) and one body fluid (BF, pleural fluid). 16 female and 16 male patients, age 25-93(mean age 57) Diagnosis included 7 normal/reactive samples (3 BMA, 1 BF and 3 PB), 12 samples with B or T lymphoproliferative disorders (LPD), 1 Multiple myeloma (MM), 6 acute leukemias (AML/ALL), 5 MDS and one paroxysmal nocturnal hemoglobinuria (PNH).
  • 20. NORMAL BM SAMPLE Living Cells = NOT Debris
  • 22. Dim CD45+CD45-ve NORMAL BM SAMPLE (CD45-/dim ANALYSIS)
  • 24. NK = Lymphs AND (NOT CD19+) NORMAL BM SAMPLE (T-CELL/ NK ANALYSIS)
  • 25. NORMAL BM SAMPLE (Grans & Monos Aanalysis)
  • 29. FLOW CYTOMETRY LAB - UHN Paperless reporting All staff members have access to analysis software and share drive Shared drive storage/reporting
  • 32. Paucicellular Cytologic Specimens (1) CSF WBC= 5 x106/L 1,315 events collected Reactive lymphoid T-cell population Rajab A, Boerner S, da Cunha Santos G, Geddie W, Ko HM, Porwit A. Ten-Color 14 antibody flow cytometry panel for immunophenotyping of paucicellular cytologic specimens. Cytometry Part B: Clinical Cytometry, 2013, Oct 25, 84, (6): 419 (abstract).
  • 33. CSF WBC= 2 x106/L 3,262 events collected B-cell LPD Paucicellular Cytologic Specimens (2)
  • 34. CSF WBC= 22 x106/L 6,560 events collected ATLL Paucicellular Cytologic Specimens (3)
  • 37. VALIDATION FOR LYMPHOMA/LEUKEMIA (PHASE 1- RESULTS) (The comparison study showed 100% concordance)
  • 38. VALIDATION FOR LYMPHOMA/LEUKEMIA (PHASE 1) SUMMARY (1) • During August 2012 – December 2013 we have analyzed 1025 samples using ST. In 94% of the cases we could render a final FCM report and 6% of cases required further immunophenotyping. • The Screening Tube is capable of enumerating major blood and bone marrow cell populations. • It can detect aberrant antigen expression on B-cells (CD5, CD10, CD20, Kappa/Lambda) • Establish B-cell clonality status • Establish B-cell maturation status (CD10/CD20) • Detecting aberrant expression on T-cells (CD3, CD5, CD4, CD8, & CD10)
  • 39. VALIDATION FOR LYMPHOMA/LEUKEMIA (PHASE 1) SUMMARY (2) • The Screening Tube can detect abnormal Myeloid populations • The Screening Tube can reduce TAT • The Screening Tube reduces the need for Hem- Path consultation • The Screening Tube can reduce costs by up to 30% • Unable to detect minor clonal plasma cell population
  • 40. Flow cytometry has recently been recommended as a significant parameter in the integrated diagnostics of patients with cytopenia and suspected MDS • Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, del CC, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013 Oct 24;122(17):2943-64. • Porwit A. Role of flow cytometry in diagnostics of myelodysplastic syndromes--beyond the WHO 2008 classification. Semin Diagn Pathol 2011 Nov;28(4):273-82. • Porwit A, van de Loosdrecht AA, Bettelheim P, Brodersen LE, Burbury K, Cremers E, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia 2014 Jun 12. • Porwit A. Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes? Curr Hematol Malig Rep. 2015 Sep;10(3):309-17 VALIDATION FOR MDS SCREENING (PHASE 2 background)
  • 41. VALIDATION FOR MDS SCREENING (PHASE 2 background) Study enrolled patients from 6 institutions (Europe, USA, Japan) 417 low grade MDS (with <5% blasts) 380 pathological controls with non-clonal cytopenias FCM analysis was performed with various antibody combinations and various flow cytometers Haematologica 2012; 97(8)
  • 42. VALIDATION (PHASE 2 background) FCM score > 2 was significantly associated with MDS diagnosis High values were associated with multilineage dysplasia, transfusion dependency and high-risk cytogenetics Della Porta et al. 2012
  • 43. FCM- score for MDS using our screening tube (NORMAL BM) Gated Myeloblasts in all nucleated cells: 1.6% (If ≥2%, FCM score= 1) Gated B-cell progenitor in CD34+ cells: 5.3% (If ≤5%, FCM score=1) Lymphocyte to myeloblast CD45 MFI ratio= 6.4 (If ≤4 or ≥7.5, FCM score=1) Granulocyte to lymphocyte SSC mode ratio: 8 (If ≤6, FCM score=1) Total FCM score= 0
  • 44. FCM- score for MDS (MDS case) Gated Myeloblasts in all nucleated cells: 3.3 (If ≥2, FCM score= 1) Gated B-cell progenitor in CD34+ cells: 0.4 (If ≤5, FCM score=1) Lymphocyte to myeloblast CD45 MFI ratio: 12.5 (If ≤4 or ≥7.5, FCM score=1) Granulocyte to lymphocyte SSC mode ratio: 4.7 (If ≤6, FCM score=1) Total FCM score= 4
  • 45. VALIDATION (PHASE 2) • 741 BM samples were analyzed within 2013 • Results of MDS score were correlated with morphological and cytogenetic evaluation in a selected group of 440 bone marrow samples from patients with full clinical information:  8 normal BM samples  207 BM samples hospital controls*  18 B-cell or plasma cell neoplasm  33 post treatment for other malignancy  21 post BM transplant  47 MPN  106 samples from patients with MDS or MDS/MPN diagnosis (based on morphological, cytogenetic and clinical findings) * Patients with cytopenia(s) with no evidence of underlying malignancy, BM samples with reactive inflammatory changes or lymphoma staging specimens without lymphoma involvement.
  • 46. RESULTS- VALIDATION (PHASE 2) Rajab A, Porwit A. Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features with one 10-color 14-antibody screening tube. Cytometry B Clin Cytom. 2015 Jul-Aug;88(4):253-60 PPN= 96% NPV= 82% PPN= 75% NPV= 86%
  • 47. RESULTS- VALIDATION (PHASE 2) Rajab A, Porwit A. Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features with one 10-color 14-antibody screening tube. Cytometry B Clin Cytom. 2015 Jul-Aug;88(4):253-60
  • 48. 10 color acute leukemia panel at University Health Network, Toronto AML 1 AML 2 AML 3 B-ALL T-ALL cytopl FITC CD65 CD36 CD71 CD58 CD7 nTdt PE CD13 CD64 CD11c CD22 CD1a cMPO ECD CD14 CD56 CD4 CD38 CD8 CD14 PC5.5 CD33 CD33 CD33 CD33 CD3 CD33 PC7 CD34 CD34 CD34 CD34 CD34 CD34 APC CD117 CD123 CD2 CD123 CD2 cCD79a APC_AlexaF700 CD7 CD19 CD10 CD10 CD10 cCD22 APC_AlexaF750 CD11b CD38 CD235a CD19 CD4 CD19 Pacific_BLUE CD16 HLA-DR CD15 CD20 CD5 cCD3 Krome Orange CD45 CD45 CD45 CD45 CD45 CD45
  • 50. CONCLUSION • Developed 14 MAb 10-color FCM tube can be applied for a quick screening for aberrant lymphoid populations and myelodysplasia-related features. • MDS score 3 or 4 is highly indicative of MDS/MDS-MPN but can also be seen in MPN. • Score 2 in patients with differential diagnosis of MDS or MDS/MPN should prompt further investigation for myelodysplastic syndrome using comprehensive FCM panel. • MDS diagnosis should always be based on integrated diagnostics (morphology, FCM, cytogenetics)
  • 51. CURRENT & FUTURE DEVELOPMENTS A. Improve the accuracy of MDS score B. Develop Ten-Color 15 Antibody Flow Cytometry Panel for Immunophenotyping of Lymphocyte population
  • 52. Improve the accuracy of MDS score Porwit A, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes- proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia 2014 Jun 12.
  • 53. Ten-Color 15 Antibody Flow Cytometry Panel for Immunophenotyping of Lymphocyte population • 80% of LPD cases we diagnosed in 2014 in blood are CLL/MBL.
  • 54. Ten-Color 15 Antibody Flow Cytometry Panel for Immunophenotyping of Lymphocyte population Ab FITC CD4 + Kappa PE CD8 + Lambda ECD CD3 + CD14 PC5.5 CD5 PC7 CD20 + CD56 APC CD10 APC-A700 CD19 APC-A750 CD200 PB CD57 +CD23 KO CD45 ICCS 2015, Abstract #88, Poster Session 2 on Monday, October 12, 2015 Ten-Color 15 Antibody Flow Cytometry Panel for Immunophenotyping of Lymphocyte population Amr Rajab, Graeme Quest, Jennifer Leung, Anna Porwit Department of Laboratory Hematology, University Health Network Toronto, ON, Canada
  • 55. CLL
  • 56. MCL
  • 58. AITL
  • 59. ACKNOWLEDGEMENTS • Anna Porwit • Jennifer Leung • Jessie Leung • Jordan Ngo • Josello Mandawi • Liz Valenzuela • May Ly • Sajid Dawji • Reza Jafari
  • 60. Thank you for your attention